Logo

MediLink Therapeutics Enters into a Collaboration and License Agreement with Roche to Develop and Commercialize YL211 for Solid Tumors

Share this
Roche

MediLink Therapeutics Enters into a Collaboration and License Agreement with Roche to Develop and Commercialize YL211 for Solid Tumors

Shots:

  • MediLink will grant Roche exclusive global rights for the development, manufacturing & commercialization of YL211. Both companies will jointly initiate the P-I clinical evaluation of YL211 at Roche’s R&D unit CICoR following which Roche will be responsible for further development & commercialization globally
  • As per the agreement, Medilink will receive an aggregate of $50M in up front & near-term milestone payments & additional development, regulatory & commercial milestone payments potentially adding to a total deal value of ~$1B plus tiered royalties
  • YL211 is an ADC that specifically targets c-Mesenchymal-epithelial transition factor (c-Met) associated with tumor formation, aggressive growth & metastasis

Ref: PR Newswire | Image: Roche

Related News:- MediLink Therapeutics Entered into a Collaboration and License Agreement with BioNTech to Develop Next-Generation Anti-Cancer Antibody-Drug Conjugate

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions